Anika Therapeutics | ANIK - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Abbott USD 8.52B 1.01B 2025-12
Agenus USD 3.46M 6.08M 2025-09
Agios Pharmaceuticals USD 89.13M 3.58M 2025-12
Anika Therapeutics USD 57.48M 509K 2025-12
Arrowhead Research USD 201.64M 112.94M 2025-12
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Halozyme Therapeutics USD 133.82M 285.84M 2025-12
Heron Therapeutics USD 43.07M 26.55M 2025-09
Insmed USD 510.44M 175.68M 2025-12
Integra LifeSciences USD 235.05M 2.86M 2025-12
Intrexon USD 9.34M 1.77M 2024-06
J&J USD 19.71B 1.48B 2025-12
Karyopharm Therapeutics USD 37.67M 1.05M 2025-09
Ligand Pharmaceuticals USD 174.93M 489.59M 2025-12
MacroGenics USD 57.22M 22.91M 2025-12
Merit Medical Systems USD 446.4M 53.95M 2025-12
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Stryker USD 4.01B 755M 2025-12
Surmodics USD 36.11M 11.81M 2024-09
Veracyte USD 362.58M 47M 2025-12
Xencor USD 54.07M 25.78M 2025-12
Zimmer Biomet Holdings USD 591.9M 700.8M 2025-12